American Society of Hematology Annual Meeting 2023

The 65th annual 2023 American Society of Hematology (ASH) Annual Meeting takes place in-person in San Diego, CA, and virtually. The ASH Annual Meeting & Exposition offers educational meetings and workshops for hematology professionals from around the world, with over 7,000 accepted abstracts representing the most cutting-edge science in hematology.

Mass General Cancer Center colleagues will join thousands of international hematologists at ASH 2023, hosting scientific workshops and presenting oral and poster abstracts.

Jeremy Abramson, MD

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients With Follicular, Mantle Cell and Hodgkin Lymphoma
Invited Speaker: Satellite Symposium
December 8 at 7:00 a.m. - 10:00 a.m.

Preliminary Results of Nathali-01: A First-in-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
Poster Presentation
December 9 at 5:30 p.m. - 7:30 p.m.

Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-stage Classical Hodgkin Lymphoma (SGN35-027 Part C)
Oral Presentation
December 10 at 5:30 p.m.

Hanny Al-Samkari, MD

Platelet Antibody Testing in Immune Thrombocytopenic Purpura
Scientific Workshop
December 8 at 2:05 p.m. - 3:20 p.m.

Avatrombopag for Adults With Early Versus Chronic Immune Thrombocytopenia
Oral Presentation
December 10 at 9:45 a.m.

PATH-HHT, a Double-blind, Randomized, Placebo-controlled Trial in Hereditary Hemorrhagic Telangiectasia Demonstrates That Pomalidomide Reduces Epistaxis and Improves Quality of Life
Oral Presentation
December 12 at 9:00 a.m. - 10:30 a.m.

Diana Cirstea, MD

Immune Profiling and Responses of Smoldering Multiple Myeloma Patients Treated in a Phase Ib Study of Pvx-410 Vaccine Targeting XBP1/CD138/CS1 Antigens, and Citarinostat, a Histone Deacetylase Inhibitor (HDACi) With and Without Lenalidomide
Poster Presentation
December 9 at 5:30 p.m. - 7:30 p.m.

Zachariah DeFilipp, MD

Maintenance Ruxolitinib Is Associated With Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults With AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial
Oral Presentation
December 10 at 5:30 p.m.

The MAGIC Algorithm Probability Predicts Long-term Outcomes and Treatment Response to Second-line Therapy for Acute Gvhd
Poster Presentation
December 10 at 6:00 p.m. - 8:00 p.m.

A Phase II Multicenter Trial of Ruxolitinib to Treat Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Cell Transplantation
Oral Presentation
December 11 at 10:30 a.m.

Aonkon Dey, BS, and Rupa Narayan, MD

Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined With Azacitidine in MDS and CMML
Poster Presentation
December 11 at 6:00 p.m. - 8:00 p.m.

Areej El-Jawahri, MD

Multi-site Randomized Trial of Inpatient Palliative Care for Hospitalized Patients Undergoing Hematopoietic Stem Cell Transplantation
Oral Presentation
December 11 at 2:45 p.m.

Multimodal Mobile Application to Address Sexual Dysfunction in Hematopoietic Stem Cell Transplant (HCT) Survivors
Poster Presentation
December 11 at 6:00 p.m. - 8:00 p.m

Amir Fathi, MD

Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations, and Beyond!
Invited Speaker: Satellite Symposium
December 8 at 11:00 a.m. - 2:00 p.m

Matthew Frigault, MD

Itacitinib for the Prevention of Immune Effector Cell Therapy-associated Cytokine Release Syndrome: Results From the Phase 2 Incb 39110-211 Placebo-controlled Randomized Cohort
Oral Presentation
December 9 at 4:15 p.m.

Phase 1 Study of CART-Ddbcma for the Treatment of Patients With Relapsed and/or Refractory Multiple Myeloma: Results From at Least 1-Year Follow-up in All Patients
Oral Presentation
December 11 at 5:00 p.m.

Amyah Harris

Changes in White Blood Cell Counts Early During Treatment of Acute Leukemia Using Differentiating Chemotherapies
Poster Presentation
December 9 at 5:30 p.m. - 7:30 p.m.

Gabriela S. Hobbs, MD

Novel Therapies, Combinations, and Clinical Trials Across MPN Care
Invited Speaker: Satellite Symposium
December 8 at 11:00 a.m. - 1:30 p.m.

Updated Findings of a Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis
Poster Presentation
December 9 at 5:30 p.m. - 7:30 p.m.

Patrick Johnson, MD

Pilot Randomized Controlled Trial of an Educational Video for Chimeric Antigen Receptor (CAR)-T Cell Therapy Recipients
Oral Presentation
December 9 at 2:30 p.m.

Longitudinal Patient-reported Outcomes and Clinical Outcomes By VES-13 and Comprehensive Geriatric Assessment in Older Adults With Aggressive Non-Hodgkin Lymphomas
Poster Presentation
December 11 at 6:00 p.m. - 8:00 p.m.

Manik Kuchroo, MD, PhD

A Phase 2 Study of Lenalidomide in Combination With Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Poster Presentation
December 10 at 6:00 p.m. - 8:00 p.m.

David Kuter, MD, DPhil

Complement Wheel: Optimizing Care for Patients With AHUS, HSCT-TMA, and PNH
Invited Speaker: Satellite Symposium
December 8 at 3:00 p.m. - 6:00 p.m.

First-Time Users of Advanced Therapies Among Adult Patients With Persistent or Chronic Primary Immune Thrombocytopenia: Patient Characteristics, Treatment Switching Patterns, and Clinical Outcomes
Oral Presentation
December 10 at 9:30 a.m.

Clinical and Economic Burden of Illness in Patients With Persistent or Chronic Primary Immune Thrombocytopenia Treated With TPO-Ras and Rituximab
Poster Presentation
December 11 at 6:00 p.m. - 8:00 p.m.

Michelle Hyunju Lee, MD

Psychiatric and Substance Use Disorders Are Independent Predictors of Treatment Response and Outcomes in United States Veterans With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Combinations
Oral Presentation
December 9 at 4:00 p.m. - 5:30 p.m.

Jelena Milosevic, PhD

Pyrimidine Starvation Is a Targetable Cancer Vulnerability: Mechanisms of Nucleotide Homeostasis
Poster Presentation
December 11 at 6:00 p.m. - 8:00 p.m.

Elizabeth K. O'Donnell, MD

A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-eligible Multiple Myeloma (The SKylaRk Trial)
Poster Presentation
December 11 at 6:00 p.m. - 8:00 p.m.

Priyanka Pullarkat, MD

Methods of Estimating Renal Function for Use in Clinical Trial Eligibility Criteria Widely Vary in Phase II and III Clinical Trials in Acute Myeloid Leukemia
Poster Presentation
December 10 at 6:00 p.m. - 8:00 p.m.

Noopur Raje, MD

BEYOND THE GUIDELINES: Clinical Investigator Perspectives on the Management of Patients With Multiple Myeloma (Part 4 of a 4-part CME-accredited Symposia Series)
Speaker: Friday Satellite Symposia
December 8 at 7:00 p.m. - 10:00 p.m.

Rachel Rosovsky, MD, MPH

Survey of Pulmonary Embolism Risk Stratification Methods in the Emergency Department and Barriers to Electronic Health Record Documentation
Poster Presentation
December 10 at 6:00 p.m. - 8:00 p.m.

Rajib Shome, PhD

Transcriptional Co-Activator P300 Promotes Extra-Medullary Disease Formation and Myeloma Disease Progression
Poster Presentation
December 9 at 5:30 p.m. - 7:30 p.m.

Jacob Soumerai, MD

Infection Outcomes and Hypogammaglobulinemia in Patients With Non-Hodgkin Lymphoma Treated With Immunoglobulin Replacement Therapy
Poster Presentation
December 10 at 6:00 p.m. - 8:00 p.m.

David Sykes, MD, PhD

An Unexpected Spontaneous Mutation Results in a New Mouse Model of Thrombopoietin Deficiency
Scientific Workshop
December 8 at 2:45 p.m. - 3:33 p.m.